Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prevention of Narcotic-Induced Nausea

This study has been terminated.
(Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated)
Information provided by (Responsible Party):
Christiana Care Health Services Identifier:
First received: October 5, 2007
Last updated: March 12, 2014
Last verified: March 2014
We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.

Condition Intervention
Drug: Saline
Drug: Phenergan

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Prevention of Narcotic-induced Nausea With Promethazine, a Randomized, Double-blind Placebo-controlled Trial

Resource links provided by NLM:

Further study details as provided by Christiana Care Health Services:

Primary Outcome Measures:
  • Number of Patients Who Became Nauseated After IV Opiate Administration. [ Time Frame: 4 hours post opiate administration ]

Enrollment: 25
Study Start Date: February 2007
Study Completion Date: November 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
Drug: Saline
10 c of saline
Active Comparator: 2
Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
Drug: Phenergan
Physician ordered dose

Detailed Description:

Patients will be randomized to one of two study groups. They will then be asked to rate their pain and nausea on a line graph. If the patient is a female of child bearing age, a urine pregnancy test will be done per standard of care. After this, an IV catheter will be placed in a vein in the patients arm. Pain medicine will be given through this IV per the doctor's order. With this medicine, patients will be given 10 milliliters (2 teaspoons) of either Sodium Chloride (salt water) or Phenergan mixed with Sodium Chloride (salt water). Phenergan is a medication typically used to help with nausea and is a common ingredient in prescription cough medicine.

After this is finished, patients will be asked to rate their pain and nausea in 30 minutes, and again 1, 2, and 4 hours later. If the doctor decides the patient is able to be discharged from the emergency room before the 4 hours are up, they will be asked to rate your pain and nausea again before going home, and the study will be stopped at that time.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Patient in Christian Care Emergency Department
  2. Require intravenous narcotics for painful condition
  3. ≥18 years of age
  4. Able to visually rate amount of pain and nausea

Exclusion Criteria:

  1. Hypersensitivity to promethazine or opioids
  2. Patient requesting anti-emetic at enrollment
  3. Narcotic administration in last 6 hours
  4. Pregnancy or currently breast-feeding
  5. Known seizure disorder
  6. Medical Instability
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00541671

United States, Delaware
Christiana Care Health Services
Newark, Delaware, United States, 19718
Sponsors and Collaborators
Christiana Care Health Services
Principal Investigator: Michael Perraut, MD Christiana Care Health Services
  More Information

Responsible Party: Christiana Care Health Services Identifier: NCT00541671     History of Changes
Other Study ID Numbers: 27002
Study First Received: October 5, 2007
Results First Received: May 29, 2012
Last Updated: March 12, 2014

Keywords provided by Christiana Care Health Services:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Dermatologic Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents processed this record on April 24, 2017